TAG laments that development for the latest oral HIV pre-exposure prophylaxis (PrEP) left out cisgender women and transgender men, but welcomes the accountability provided—albeit belated—by the U.S. Food and Drug Administration (FDA) to rectify this inequity.
The Act Now End AIDS coalition is deeply troubled by the contents of Ben Ryan’s September 11 Guardian article “'Rick Scott had us on lockdown:' how Florida said no to $70m for HIV crisis." The article, which reflects four years of investigative journalism by Ryan with additional reporting by Noah Pransky, paints a detailed picture of how Florida’s then-governor, Rick Scott, refused Medicaid expansion and federal dollars to fight the epidemic from 2015-2017
In early August, FDA announced approvals of two fixed-dose combination (FDC) antiretroviral drug products for use with other antiretroviral agents in the treatment of HIV-1 infection: GlaxoSmithKline's Epzicom® (abacavir/lamivudine) and Gilead Sciences, Inc.'s Truvada® (tenofovir disoproxil/emtricitabine).